Tesamorelin Dosing & Protocols — Research Reference

Tesamorelin is a stabilized GHRH analog with FDA-approved research in HIV-associated lipodystrophy. It is widely studied in visceral-adipose-tissue (VAT) and metabolic research models. This guide compiles standard dosing references from the published clinical-trial literature.

Reconstitution for Research

Tesamorelin is supplied lyophilized. Standard reconstitution: 1–2 mg with 1 mL bacteriostatic water. Refrigerated stability is shorter than many GHRH analogs — confirm window with COA, typically 7–14 days.

Reference Dose Ranges in Published Research

| Research model tier | Typical range | Notes | |---|---|---| | Standard research dose | 1–2 mg subcutaneous, once daily | The 2 mg/day dose is the FDA-approved research reference for VAT reduction | | Lower-tier exploration | 0.5–1 mg daily | Some metabolic-only research uses lower doses |

Scheduling

Daily subcutaneous administration, typically evening, to align with endogenous nocturnal GH-pulse window. Steady-state IGF-1 elevation is reached at ~2 weeks.

Cycling in the Published Literature

Published research often uses 26-week continuous administration cycles. Discontinuation produces VAT regain within 26 weeks, supporting the continuous-administration model.

Common Research Endpoint Markers

Visceral adipose tissue (CT or MRI measurement), IGF-1, lipid panel, triglycerides, fasting glucose, insulin sensitivity. Hepatic markers should be tracked given the GH-axis effect on glucose metabolism.

Common Research Pairings

Most-cited research as monotherapy. Some translational research pairs with GLP-1 agonists to study combined metabolic + visceral-adipose endpoints.

Storage & Stability

Lyophilized at 2–8 °C protected from light. Reconstituted refrigerated with shorter stability window than other GHRH analogs.

Frequently Asked Questions

Why daily dosing for tesamorelin but weekly for tirzepatide?

Tesamorelin's GHRH-analog activity has a short half-life (~30 minutes plasma); daily dosing supports the desired pulsatile GH-axis pattern. Tirzepatide has structural modifications producing a multi-day half-life.

How does tesamorelin differ from CJC-1295?

Both are stabilized GHRH analogs. Tesamorelin uses N-terminal modification; CJC-1295 No-DAC also uses backbone stabilization. CJC-1295 with DAC adds albumin-binding extending half-life dramatically. See the tesamorelin vs CJC-1295 comparison.

Research-Use Disclosure

All content is provided strictly for laboratory research purposes. Compounds discussed are research chemicals and are not for human or veterinary consumption. Dosing ranges referenced below are summaries of published preclinical and clinical research literature compiled for laboratory reference only — they are not medical recommendations.